← Back to Search

Interrupting Sitting for Sedentary Lifestyle

N/A

Waitlist Available

Research Sponsored by University of California, San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

screened to sit for 8 or more hours per day, perform less than 60 sit-to-stand transitions per day & engage in less than 20 minutes of moderate-to-vigorous physical activity (MVPA) per day

ambulatory

Must not have

poorly controlled hypertension (Systolic Blood Pressure ≥165 or Diastolic Blood Pressure ≥100);

type 2 diabetes using insulin or with poor glycemic control (greater than 10% for all participants);

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 hours

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether different interruptions to prolonged sitting improve metabolism in postmenopausal women.

Who is the study for?

This trial is for postmenopausal women over 55 who are generally sedentary, with a BMI of 25-45 kg/m2. They must be medically stable, not involved in other physical activity studies, and able to commit to the study's requirements. Exclusions include those with significant weight changes recently, uncontrolled diabetes or hypertension, certain chronic illnesses like active cancer or HIV/AIDS, smokers, and those on specific medications.

What is being tested?

The trial examines if interrupting sitting time with frequent sit-to-stands or standing more can improve metabolism as part of healthy aging. It's a randomized crossover clinical trial where participants will experience different conditions to compare effects on their health markers.

What are the potential side effects?

Since this intervention involves lifestyle changes rather than medication, side effects may include muscle soreness or fatigue from increased activity. However, these are typically mild and decrease as individuals become accustomed to more movement.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I sit for 8+ hours, stand up <60 times, and do <20 mins of exercise daily.

Select...

I can walk on my own without help.

Select...

I am 55 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My blood pressure is not higher than 165/100.

Select...

I have type 2 diabetes and use insulin or my blood sugar control is poor.

Select...

I do not use tobacco products or e-cigarettes.

Select...

I have been diagnosed with a drop in blood pressure when standing up.

Select...

I or my close family member have had a blood clot.

Select...

I regularly use medication to widen my blood vessels and have a high risk of heart problems.

Select...

I am mentally capable of understanding and following the study's requirements.

Select...

I have type 1 diabetes.

Select...

I regularly take medication to suppress my immune system.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Insulin

Postprandial glucose

Secondary study objectives

Blood pressure

Flow mediated dilation

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Stand More (Protocol C)Experimental Treatment1 Intervention

Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.

Group II: Frequent Sit-to-Stands (Protocol B)Experimental Treatment1 Intervention

Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.

Group III: Control Condition (Protocol A)Active Control1 Intervention

Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Frequent sit-to-stands

2016

N/A

~10

0 / 12Eligibility criteria met